carlisle & Associates
generic drug updates News contact carlisle medical
news
generic drug updates
Generic of Maxalt® Launches
Released: 01/07/2013
By: Mike Partridge, RPh

On December 31, 2012, Apotex received final FDA approval for and commenced shipping the generic equivalent for Merck’s branded product, Maxalt® (rizatriptan benzoate) tablets. Maxalt® had estimated total U.S. annual sales of approximately $336 million.

Maxalt® is indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old.


<<Back
 
Company News Releases
Generic Drug Updates
Newsletter Subscription
Newsletter Login
 
 
 
 
 
© Copyright 2019 Carlisle Medical, Inc.
Twitter Twitter Twitter Twitter
disclaimer site map disclaimer